Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2012-06-11 AGM Information
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France
AGM Information Classification · 99% confidence The document explicitly announces that Innate Pharma will hold its 'Annual General Meeting of Shareholders ("AGM") on June 28, 2012'. It details the logistics, required documentation ('Notice of Meeting'), and procedures for shareholder participation and voting. This content directly relates to the materials and announcements surrounding the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4030 chars) is substantial enough that it is not merely a brief announcement of a report (RPA), but the substantive notice itself.
2012-06-11 English
“L’immunologie et l’immunité innée, clés du traitement contre le cancer” telle est la conclusion de la table ronde qui a réuni un panel d’experts dont les deux prix Nobel de Médecine 2011
Regulatory Filings Classification · 95% confidence The document announces the success of a roundtable discussion titled 'L'immunité innée, de la découverte révolutionnaire à la révolution thérapeutique' held on May 15, 2012, featuring Nobel laureates and experts discussing cancer immunotherapy. It summarizes key takeaways and includes 'About' sections for the participating companies (Bristol-Myers Squibb and Innate Pharma). Crucially, it contains forward-looking statements ('Déclarations prospectives') referencing the 10-K form for BMS, but the document itself is a press release summarizing an event, not the official 10-K or a comprehensive quarterly report (IR). It is an announcement of news/research findings related to the industry, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially an 'Investor Presentation' (IP) if it were a slide deck, but given the format and content (press release style summary of an event), RNS is the most appropriate fallback for non-standard announcements.
2012-05-21 French
“Immunology and Innate Immunity are Keys to Cancer Treatment” Conclusions of the Roundtable of internationally renowned speakers, including winners of the 2011 Nobel Prize in Medicine
Regulatory Filings Classification · 95% confidence The document is a press release dated May 21, 2012, announcing the success of a roundtable discussion titled 'Innate immunity: from revolutionary discovery to revolution in therapy' held on May 15th. It quotes key participants (including Nobel laureates) and provides summaries of the scientific discussions regarding cancer immunotherapy and innate immunity. It includes standard sections like 'About Bristol-Myers Squibb' and 'About Innate Pharma', and concludes with forward-looking statements and contact information. This format is characteristic of an initial announcement of news or findings, rather than a full regulatory report (like 10-K or IR) or a transcript of a call (CT). Since it is announcing key results and insights from a scientific event, it most closely aligns with an Earnings Release (ER) in terms of being a primary, timely announcement of company-relevant information, although it is not strictly financial earnings. Given the options, and recognizing it as a high-level announcement of scientific/strategic progress, it is best classified as an Earnings Release (ER) as it communicates key developments, or potentially a Regulatory Filing (RNS) if ER is too narrow. However, ER often covers major strategic/scientific milestones in the pharma sector. Given the content focuses on scientific breakthroughs and industry collaboration, it functions as a major corporate announcement. Since there is no specific category for 'Scientific Press Release' or 'Event Summary', and it is not a formal report, ER is the closest fit for a major, timely announcement of results/progress, or RNS as a general announcement. Given the context of financial reporting databases, ER is often used for significant non-financial announcements that impact future outlook. I will lean towards ER as it communicates 'results' of the roundtable discussion, which drives future expectations.
2012-05-21 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d’affaires au 31 mars 2012 et fait le point sur sa trésorerie
Earnings Release Classification · 99% confidence The document is titled "INNATE PHARMA ANNONCE SON CHIFFRE D'AFFAIRES AU 31 MARS 2012 ET FAIT LE POINT SUR SA TRÉSORERIE" (Innate Pharma announces its revenue for March 31, 2012, and provides an update on its cash position). It reports key financial figures (revenue of 3.0 million euros for Q1 2012, cash position of 41.6 million euros as of March 31, 2012) immediately following the period end. This structure—announcing key period results briefly—is characteristic of an Earnings Release (ER). Although it mentions the availability of the full Annual Report ('Document de Référence 2011'), the primary content is the summary of the quarterly performance, making ER the most appropriate classification over RPA or 10-K. The document length (4732 chars) is substantial enough to be the release itself, not just a notification. Q1 2012
2012-05-10 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first quarter of 2012 and updates on its cash position
Earnings Release Classification · 98% confidence The document is titled "INNATE PHARMA ANNOUNCES 1Q2012 REVENUE AND UPDATES ON ITS CASH POSITION" and provides key financial highlights (revenue, cash position) for the first quarter (1Q2012). This structure—announcing key figures for a recent period without the full detail of a comprehensive report—is characteristic of an Earnings Release (ER). Although it mentions the availability of the 'Annual report and Reference Document' for 2011, the primary content focuses on the Q1 2012 performance update. Since it is a summary announcement of period results, ER is the most appropriate classification over IR (Interim Report) or 10-K (Annual Report). Q1 2012
2012-05-10 English
Document de référence et rapport financier annuel d'Innate Pharma
Annual Report Classification · 100% confidence The document is a 'Document de Référence' (Reference Document) which serves as the French equivalent of an Annual Report (10-K). It contains comprehensive financial statements, audit reports, management discussion and analysis, and corporate governance information for the fiscal year 2011. It is a full-length regulatory filing submitted to the AMF, not an announcement or a summary. FY 2011
2012-04-26 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.